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Summary Background Improvements in knowledge of
molecular mechanisms in cancer are the basis for new
studies combining chemotherapy with targeted drugs. Inhi-
bition of the epidermal growth factor receptor (EGFR) by
erlotinib or cetuximab has limited or no activity, respective-
ly, in pancreatic cancer. The crosstalk between EGFR and
mammalian target of rapamycin (mTOR) pathways is a
potential mechanism of resistance; therefore we conducted
a study to explore safety and efficacy of multiple pathway
inhibition by cetuximab and everolimus in combination with
capecitabine. Methods Safety and efficacy of fixed standard
dose cetuximab in combination with various dose levels of
everolimus (5–10 mg/day) and capecitabine (600–800 mg/
m2 bid, 2 weeks every 3 weeks) were investigated in a phase
I/II study in patients with advanced pancreatic cancer. The
primary endpoint was objective response. Results Sixteen
patients were treated in the phase I part at two dose levels.
Mucositis, rash and hand-foot syndrome were dose-limiting
toxicities. Dose level 1 (everolimus 5 mg/day, capecitabine
600 mg/m2 bid for 2 weeks every 3 weeks and cetuximab
250 mg/m2 weekly) was considered the maximum tolerated
dose (MTD). Of 31 patients in the phase II part, partial
response was documented in two patients (6.5%) and five
(16.1%) had stable disease. Median overall survival was
5.0 months (CI 3.1–6.8). Conclusion The schedule of cape-
citabine, everolimus and cetuximab resulted in considerable
epidermal and mucosal toxicities and prevented escalation
to optimal dose levels. Because of toxicity and low efficacy
this treatment combination cannot be recommended for
treatment in pancreatic cancer patients.
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Introduction
Pancreatic cancer patients have one of the worst prognoses
among all cancer types with an overall survival rate of less
than 5% [1]. Since the publication of Burris in 1997 gemci-
tabine is still considered as the standard treatment for most
patients with pancreatic cancer [2]. Several randomized
clinical trials comparing gemcitabine in combination with
other chemotherapeutic drugs have not resulted in survival
improvement [3].
Moving away from the paradigm that combination ther-
apy must be gemcitabine based, a strategy that has invari-
ably failed, Conroy et al. recently demonstrated in a
randomized clinical trial a significant survival advantage
with the gemcitabine free combination chemotherapy regi-
men FOLFIRINOX as compared with gemcitabine [4]. Al-
though patients were highly selected and toxicity was
considerable, this trial opens the way to new treatment
strategies in advanced pancreatic cancer.
S. Kordes (*) :D. J. Richel :H.-J. Klümpen :M. J. Weterman :
A. J. W. M. Stevens : J. W. Wilmink
Department of Medical Oncology,
Academic Medical Center Amsterdam,
Meibergdreef 9,
1105 AZ Amsterdam, The Netherlands
e-mail: s.kordes@amc.uva.nl
Invest New Drugs (2013) 31:85–91
DOI 10.1007/s10637-012-9802-1
Significant improvements in our knowledge of the mo-
lecular mechanisms involved in cancer development and
progression, and the availability of drugs interfering with
aberrant activity in various signaling pathways, have subse-
quently resulted in numerous clinical trials combining conven-
tional chemotherapy with various targeted drugs. The EGFR/
MAPK and PI3K/Akt/mTOR pathways are often dysregulated
and considerable evidence supports the important role of these
pathways in the biology of pancreatic cancer [5, 6]. Several
targets in these pathways are potential candidates to achieve
inhibition of aberrant signaling. Erlotinib, a tyrosine kinase
EGFR inhibitor, was one of the first FDA approved tyrosine
kinase inhibitors. In a randomized clinical trial in pancreatic
cancer patients, erlotinib in combination with gemcitabine
induced a statistically significant improvement in survival,
although the two weeks survival benefit was considered clin-
ically not meaningful [7]. Targeting EGFR with the monoclo-
nal antibody cetuximab in combination with gemcitabine
failed to demonstrate a survival advantage[8]. mTOR is an
important signaling molecule in the PI3K pathway and inhibi-
tion of mTOR could inhibit tumor growth in pancreatic cancer
xenograft models [9]. However, in a clinical study no benefit
was demonstrated using the mTOR inhibitor everolimus as a
single agent in second line [10]. Possible explanations for the
relative insensitivity to drugs targeting only one aberrant mol-
ecule is the heterogeneous molecular pathogenesis of pancre-
atic cancer leading to deviant activation of multiple signaling
pathways and the intensive crosstalk between these pathways
[11, 12]. Although some tumorswith specific crucialmutations
are sensitive to mono-targeted therapies, such as gastro-
intestinal stromal tumor and imatinib, for most cancer
types including pancreatic cancer this is not the case
[13, 14]. Exploration of drug combinations targeting
multiple pathways is therefore an interesting strategy
to overcome drug resistance. Rational targets for this
combined approach in pancreatic cancer are EGFR and
mTOR, leading to synergistic anticancer activity as has
been demonstrated in pre-clinical models [15–20].
Therefore we explored in the present study the feasibility
and efficacy of a triple drug combination consisting of cetux-
imab, everolimus and capecitabine in patients with advanced
pancreatic cancer. In an earlier phase I study we demonstrated
that everolimus (10 mg daily) in combination with capecita-
bine (1000 mg/m2 BID) was a safe and tolerable regimen [21].
In the present study gemcitabine was replaced by capecitabine
because gemcitabine in combination with everolimus induced
severe bone-marrow toxicity already at the gemcitabine dose
level of 600 mg/m [22]. The failure of gemcitabine based
combination regimens was also taken in to account. The
monoclonal antibody cetuximab instead of erlotinib was cho-
sen because of potential pharmacokinetic interactions between
erlotinib and mTOR inhibitors (at the level of cytochrome P
(CYP) metabolizing enzymes) [23, 24].
Patients and methods
Study design and statistics
This multicenter open-label phase I/II trial consisted of two
parts: the phase I part was traditionally designed with inter-
patient dose escalation in cohorts of three to six patients
with the primary end point of protocol-defined dose limiting
toxicity (DLT) and Maximum Tolerated Dose (MTD) [25].
The phase II part was designed to determinate the efficacy
and feasibility of the combination of everolimus, capecita-
bine and cetuximab. Primary endpoint of this part of the
study was response rate. Patients were defined as responders
when a complete response (CR) or partial response (PR) by
response evaluation criteria in solid tumors (RECIST) 1.0
was seen. Secondary endpoints were time to treatment fail-
ure (TTF), overall survival (OS), one-year survival rate and
the toxicity profile according to NCI–CTC v3.0. TTF and
OS were calculated by the Kaplan-Meier method, measured
from the date of treatment initiation to the date of docu-
mented progression and death of any cause, respectively. All
analyses were conducted on an intention-to-treat basis and
were performed using SPSS version 18.0.2.
The phase II part was designed in two stages (Simon two-
stage optimal design) with an early stopping rule for efficacy:
if no objective responses were to be observed within the first
14 patients treated at the MTD, the trial was to be halted,
because this event (0/14) has a probability of <0.05 if the true
response rate is 0.20.
The study was conducted according to the ethical princi-
ples of the Declaration of Helsinki and Good Clinical Prac-
tice and was approved by health authorities and the
independent ethics committee of the Academic Medical
Center Amsterdam. The trial is registered on the USA NCI
Web site www.ClinicalTrials.gov (NCT01077986)
Patients
Patients with cytological or histological confirmed local-
ly advanced or metastatic adenocarcinoma of the pan-
creas were eligible. Further inclusion criteria comprised
an Eastern cooperative oncology group/World health
organization (ECOG/WHO) performance status of 0, 1
or 2, measurable lesions on CT according to RECIST
1.0 criteria (for the phase II part of the study), age
eighteen years of age or older and a life-expectancy of
at least three months. Patients had to be mentally, phys-
ically and geographically able to undergo treatment and
follow-up. Adequate renal, liver and bone marrow func-
tion was necessary. Laboratory values accompanied
hereby were serum creatinine <150 μmol/L, bilirubin
<1.5x upper limit of laboratory normal (ULN), aspartate
aminotransferase and alanine aminotransferase <2.5x
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ULN or <5.0x in case of liver metastasis, white blood
cell count >3.0x109, platelets >100x109, respectively.
Patients were not eligible if they had previous treat-
ment with an mTOR inhibitor. Other exclusion criteria
included pregnancy and lactation, clinical or radiological
evidence of central nervous system metastasis at time of
enrollment, known hypersensitivity to everolimus or
other rapamycins or to its excipients, any severe and/
or uncontrolled medical conditions, such as clinically
significant heart conditions or myocardial infarction in
6 months prior to randomization, uncontrolled diabetes
as defined by fasting glucose above 1.5x ULN, active
or uncontrolled infection, serious liver disease and se-
verely impaired lung function, or a serious concomitant
systemic disorder that would compromise the safety of
the patient, at the discretion of the investigator. Written
informed consent was obtained from each patient.
Treatment
Treatment was administered in a 3-week regimen consisting
of continuous daily oral everolimus, weekly cetuximab, and
capecitabine for 14 days followed by 7 days rest. For the phase
I part, dose escalations were performed for everolimus and
capecitabine, according to Table 1. Cetuximab was given at a
fixed dose of 250 mg/m2, with a start-up dose of 400 mg/m2.
If one of three patients experienced dose-limiting toxicity
(DLT), three more patients were included at the same dose
level. If two or more patients experienced DLT, the previous
dose level was considered the MTD. All patients of the
phase II part of the study were treated at the MTD.
DLTs were defined as any of the following adverse events as
defined by the common terminology criteria for adverse events
version 3.0 (CTCAE) in the first two cycles: grade 4 neutrope-
nia lasting>5 days or febrile neutropenia grade 3; grade 4
thrombocytopenia and grade≥3 red cell count; grade≥2 vomit-
ing and grade≥3 of any other toxicity despite supportive treat-
ment, except rash, which was defined as DLT at grade 4.
In the phase II part, dose modifications were predefined
for each drug. Everolimus dose was reduced in case of grade
3 toxicity or recurrence of grade 2 non-hematological tox-
icity or thrombocytopenia after interruption. Everolimus was
discontinued in case of grade 4 toxicity or recurrence of grade
3 hematological toxicity after dose reduction. Capecitabine
had to be withheld in case of toxicity grade≥2 until recovery
to grade≤1. Dose modifications were dependent on severity
and frequency of toxicity, as defined in the protocol. Cetux-
imab had to be delayed for up to two consecutive infusions in
case of grade ≥3 skin toxicity whereas doxycyclin 100 mg
daily and local metronidazole treatment was initiated. The
same dose level was restarted if toxicity resolved to grade≤
2, with continuation of doxycyclin treatment. At second or
third recurrence of grade 3 toxicity, dose was reduced to
200 mg/m2 and 150 mg/m2, respectively. Cetuximab was
discontinued in case of withholding more than 2 infusions,
fourth recurrence of skin toxicity grade≥3, or an allergic/
hypersensitivity reaction grade≥3. Treatment was continued
until unacceptable toxicity, disease progression, withdrawal of
informed consent by the patient or any other reason why
continuation was not in the best interest of the patient. Re-
sponse assessment by CT-scan (RECIST 1.0) was done at
baseline and every 9 weeks during active treatment.
Results
Patients
In total 43 patients were enrolled between February 2009
and June 2010. Three patients were excluded from analysis
because of major violation of the inclusion criteria; one
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1 5 600 250
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bid twice daily
Table 2 Patient demo-
graphics and disease
characteristics
WHO World Health Or-
ganization DL Dose
Level
aPhase II included 7
patients of the DL1 co-
hort and 24 patients of
the phase II cohort





Median Age 57.9 61
Range 39–78 45–69
Gender
Male 13 (42) 6 (67)
Female 18 (58) 3 (33)
WHO performance status
0 16 (52) 5 (56)
1 10 (32) 3 (33)




4 (13) 1 (11)
Metastatic 27 (87) 8 (89)
Localization of primary
Head 23 (74) 8 (89)
Tail/corpus 8 (26) 1 (11)
Line of therapy
First line 22 (71) 6 (67)
≥ Second line 9 (29) 3 (33)
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patient in the phase I part of the study received eight cycles
of treatment, while in retrospect no pancreatic cancer cells
were seen in pathology. Two patients in the phase II part
experienced rapid deterioration between signing informed
consent and start of treatment.
Table 2 summarizes the baseline characteristics of all 40
eligible patients, separately for each dose level.
Phase I
Sixteen patients were enrolled in the phase I part of this
study. Dose level I was expanded to six patients because 1
patient developed grade 3 mucositis as DLT. The same
patient discontinued treatment because of cerebral infarction
6 weeks after start of treatment. Because of vascular
problems in the medical history of the patient, this compli-
cation was considered not to be related to study medication.
Nonetheless, we decided to include an additional patient in
this dose level. In the first cohort of dose level II one patient
developed grade 3 hand-foot syndrome as DLT. Therefore
this dose level was expanded to six patients. One of those
patients developed grade 3 hand-foot syndrome and muco-
sitis. These were not considered to be DLTs, because by
mistake one additional week of capecitabine was taken by
the patient in the first cycle and symptoms resolved after
3 weeks of interruption and the original dose could be
restarted. Because two other patients with progressive dis-
ease within the first cycle, were not assessable for toxicity,
three additional patients were included in DL2. Subsequent-
ly one patient developed grade 4 rash and three patients had
grade 3 mucositis as DLTs. Due to the five DLTs in DL2,
DL1 was considered as the MTD and the recommended
dose for the phase II part.
Table 3 Dose interruptions and reductions
Interruptions Reductions
Cycles (%) Patients (%) Cycles (%) Patients (%)
Total DL2 10 (40) 5 (56) 5 (20) 5 (56)
Capecitabine 5 (20) 4 (44) 1 (4) 1 (11)
Everolimus 4 (16) 4 (44) 4 (16) 4 (44)
Cetuximab 1 (4) 1 (11) 0 (0) 0 (0)
Total phase 2 22 (20) 8 (26) 6 (5) 6 (19)
Capecitabine 6 (5) 3 (10) 5 (4) 5 (16)
Everolimus 5 (4) 5 (16) 1 (1) 1 (3)
Cetuximab 11 (10) 5 (16) 0 (0) 0 (0)
Total cycles: 25 in dose level 2 (DL2), 113 in phase 2. Total patients: 9
in DL2 and 31 in phase 2
Table 4 Treatment
related toxicity
DL Dose Level a Phase
II includes 7 patients
from DL1 and 24 from
phase II
31 patients in phase II analysisa 9 patients in DL2
Any grade (%) Grade 3–4 (%) Any grade (%) Grade 3–4 (%)
Hematologic
Anemia 14 (45) 1 (3) 6 (67) 0 (0)
Neutropenia 7 (23) 0 (0) 5 (56) 0 (0)
Thrombocytopenia 8 (26) 0 (0) 3 (33) 0 (0)
Non hematological
Rash 24 (77) 6 (19) 6 (67) 3 (27)
Mucositis 14 (45) 4 (13) 6 (67) 4 (36)
Fatigue 13 (42) 4 (13) 4 (44) 1 (9)
Diarrhea 10 (32) 4 (13) 3 (33) 0 (0)
Hand-foot syndrome 10 (32) 2 (6) 1 (11) 2 (18)
Infection 5 (16) 1 (3) 2 (22) 2 (18)
Nausea/vomit 16 (52) 1 (3) 6 (67) 0 (0)
Hypokalemia 17 (55) 4 (13) 1 (11) 0 (0)
Hyperglycaemia 19 (61) 8 (26) 5 (56) 1 (18)
Total unique patients 31 (100) 23 (74) 9 (100) 8 (89)
Table 5 Objective treatment response
Response N031(%) CI
PR 2 (6.5) 1.1–18.8
SD 5 (16.1) 6.2–31.2
PD 17 (54.8) 37.9–71.1
Not assessed 7 (22.6) 10.6–38.8
Objective Response ratea 2 (6.5) 1.1–18.8
Disease Control rateb 7 (22.6) 10.6–38.8
PR partial response, SD stable disease PD progressive disease, CI
confidence interval a Objective response rate0PR b Disease Control
rate0PR+SD
88 Invest New Drugs (2013) 31:85–91
In Table 4 all toxicity for the nine patients in dose level 2 is
depicted. In these nine patients, a total of 25 complete cycles
were given, with a median of 2 (range 0–10) cycles per patient.
Dose reductions and interruptions are depicted in Table 3.
Phase II
Safety and toxicity
In the phase II part of this study, 24 eligible patients were
enrolled. When combined with the seven patients treated at
MTD in the phase I part, a total of 31 patients could be
evaluated according to the protocol. In these 31 patients, a
total of 113 complete cycles were given, with a median
(range) of 3.0 (0–20) cycles per patient. Dose reductions
and interruptions are depicted in Table 3. Table 4 represents
the treatment related toxicity. The most common grade 3/4
toxicities of the phase II part included hyperglycemia (26%),
rash (19%), mucositis (13%) and fatigue (13%).
Efficacy and survival
Table 5 summarizes the objective response observed in the
31 treated patients (71% first line, 29% second line) at the
MTD level. Out of 31 patients, 24 patients were evaluable
for response. Seven patients were not evaluable for response
due to events before the first planned CT-evaluation: two
patients were clinically progressive, one patient died (as
described in the phase I part) and three patients stopped
treatment because of treatment related toxicity (grade 3
diarrhea, intolerable rash). One patient refused further
treatment. These seven patients were considered as non-
responders.
We observed two (6.5% CI: 1.1–18.8%) partial responses
according to RECIST 1.1. Five (16.1% CI: 6.2–31.2%)
patients had stable disease, giving a disease control rate of
23.8%. Seventeen (54.8% CI: 37.9–71.1%) patients had
progressive disease.
Overall survival of the 31 patients treated at MTD was
5.0 months (CI 3.1–6.8 months) (Fig. 1). The one-year
survival rate was 12,9%. Time to treatment failure was
2.3 months (CI 1.7–2.8 months).
Table 6 summarizes overall survival differences between
groups based on differences in baseline characteristics, mea-
sured by KM-method and a log-rank test. Overall survival
for first line patients was 5.0 (CI 4.1–5.9) months, and for
second line patients 3.6 months (CI 0.0–7.7) months, which
was not a significant difference.
Fig. 1 Kaplan Meier curve of overall survival of all patients treated at
the maximum tolerated dose. Median survival is 5.0 months (CI 3.1–
6.8)+censored patients
Table 6 Kaplan-Meyer analysis
for overall survival, effect of
baseline characteristics
WHO World Health Organiza-
tion CI Confidence Interval
Total Censored Median survival (Months, CI) 1 year survival (%) Logrank_p
All Patients 31 4 5.0 (3.1–6.8) 12.9
Sex
Female 18 0 5.0 (4.2–5.7) 5.6 0.203
Male 13 4 4.5 (1.7–7.3) 23.1
Age
<65 24 2 4.5 (1.2–7.7) 12.5 0.112
≥65 7 2 10.2 (0.0–20.5) 14.3
WHO performance status
0 16 4 5.2 (4.1–6.4) 25.0 0.093
1 10 0 4.5 (0.1–8.8) 0.0
2 5 0 2.3 (1.9–2.7) 0.0
Metastasis
Locally advanced 4 1 5.2 (2.0–8.4) 25.0 0.547
Metastatic 27 3 4.9 (2.5–7.3) 11.1
Line of therapy
First line 22 3 5.0 (4.1–5.9) 18.2 0.603
≥Second line 9 1 3.6 (0.0–7.3) 0.0
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Discussion
The MTD for everolimus and capecitabine in combination
with cetuximab (cetuximab 250 mg/m2 weekly) was already
reached at the first dose level (everolimus 5 mg daily, and
capecitabine 600 mg/m2 BID). The DLTs were mucositis,
rash and hand-foot syndrome. In the phase II part of this
study the incidence of grade 3–4 hyperglycemia, a well
known complication of everolimus, was considerable and
seems even to be higher compared to studies with ever-
olimus alone. Despite the relative low dose level of ever-
olimus (5 mg) the incidence of severe mucositis (13% grade
3–4) was still considerable and also seems to be higher
compared to trials with everolimus monotherapy (10 mg).
In other studies using single agent everolimus the incidence
of grade 3–4 mucositis was 1–7% [26, 27]. In our previous
phase I study (Deenen et al.) with everolimus 10 mg and
capecitabine 500–1000 mg/m2, mucositis was not dose-
limiting, however grade 1–2 mucositis was present in 50%
of the patients [21]. Thus, the addition of cetuximab resulted
in more toxicity and prevented dose escalations of ever-
olimus and capecitabine to more optimal dosages [28].
Although the underlying mechanism is unclear, co- admin-
istration of three agents with overlapping toxicities may be
an important explanation for the excessive mucosal and/or
epidermal toxicities seen in this study. Because the study of
Deenen et al. demonstrated no pharmacokinetic interactions
between everolimus and capecitabine, and monoclonal anti-
bodies do not interfere at pharmacokinetic level, the in-
creased toxicity is probably caused by pharmacodynamic
interaction between the three drugs.
The objective response rate was only 6.5% (CI 1.1–18.8)
with an overall survival of 5 months. In the first line cohort
the OS was also 5.0 months, which even seems to be slightly
inferior in comparison with gemcitabine as first line treat-
ment [2]. In preclinical studies with cell lines of non small
cell lung, pancreatic, colon, and breast cancer combined
inhibition of mTOR and EGFR resulted in a potentiation
of anti cancer activity and resensitization of cell lines resis-
tant to EGFR inhibitors [15–18, 29]. Despite these promis-
ing preclinical results, exploration of this strategy in
pancreatic cancer patients in the present study was disap-
pointing. Possible reasons for clinical resistance to this
treatment combination are the following. Toxicity prevented
the administration of everolimus at optimal dosages. Ever-
olimus shows most effective mTOR inhibition at a dose of
10 mg, and capecitabine monotherapy showed the optimal
efficacy at 1000–1250 mg/m2 (BID) [28, 30, 31]. Secondly,
the desmoplastic nature of pancreatic cancer with a high
fibrotic component and minimal vascularization might pre-
vent an adequate drug penetration, especially a large mole-
cule like the monoclonal antibody cetuximab. Another, in
various cancer types well established, cause of resistance to
anti-EGFR treatment is KRAS mutation, predominantly
present in pancreatic cancer cells, which accounts for con-
stitutive signaling directly downstream of EGFR. However,
inhibitors of EGFR still show efficacy in some KRAS
mutated pancreatic cancer cell lines [32].
In conclusion, dose escalation of everolimus and capeci-
tabine in the present triple drug schedule with cetuximab
was not possible because of severe, especially epidermal
and mucosal, toxicity. At the relative low everolimus and
capecitabine dosages in the phase II part of this study the
toxicity was still considerable, leading to dose interruptions
and adaptations. Considering the toxicity, the response rate
of 6.5%, and median survival of 5 months in first line treated
patients, this regimen does not deserve further exploration in
pancreatic cancer patients.
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